Compare CIVI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVI | SUPN |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2011 | 2012 |
| Metric | CIVI | SUPN |
|---|---|---|
| Price | $29.21 | $45.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $40.60 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.86 | N/A |
| Revenue | ★ $4,711,808,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.29 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $22.79 | $29.16 |
| 52 Week High | $55.35 | $57.65 |
| Indicator | CIVI | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 43.24 |
| Support Level | $26.70 | $44.37 |
| Resistance Level | $28.10 | $47.00 |
| Average True Range (ATR) | 1.26 | 1.56 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 92.44 | 55.51 |
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.